Amplia Therapeutics Ltd.ASX: ATX

Quarterly Activities/Appendix 4C Cash Flow Report

Jul 28, 2026 at 6:29 PM EDT · Issued by Amplia Therapeutics Ltd. via ASX

Filed with ASX · Jul 28, 2026 at 6:29 PM EDT

On 6ix: 6ix.com/news/quarterly-activitiesappendix-4c-cash-flow-report-725

ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 29 July 2026 ASX RELEASE QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – June 2026 Key Highlights from the Quarter • ACCENT Trial:...

View Attachment

6ix hasn’t read this filing yet.

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

Notice of Annual General Meeting/Proxy FormJul 27
Amplia Announces Publication of New FAK Inhibitor Patent ApplicationJul 9
Amplia Announces Appointment of Brett Carter to BoardJul 7
Amplia Announces Changes to Board’s Leadership RolesJul 6
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic CancerJun 22

Later from Amplia Therapeutics

Scientific Paper Studies of narmafotinib - Pancreatic CancerJul 30
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now OnlineJul 31
Amplia signs Collaboration and Supply Agreement with LillyAug 3
Bioshares Biotech Summit PresentationAug 5
CEO Managing Director Presentation to Annual General MeetingAug 27

All Amplia Therapeutics news releases

Follow Amplia Therapeutics into a list and get an email when it puts out news.

Follow Amplia Therapeutics